Newsfile Corp
09 Dec 2025, 17:00 UTC · 40w ago
Verdict
Headline leans bearish. We score MLTX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
MoonLake's stock lost nearly 90% of its value following Phase 3 trial results for sonelokimab that analysts described as 'disastrous.'
More negative than 99% of claims this week
A class action lawsuit alleges MoonLake misrepresented the efficacy of its drug candidate sonelokimab by claiming superiority over other monoclonal antibodies despite lacking evidence.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 97% of claims this week
The lawsuit claims MoonLake repeatedly and knowingly omitted material facts about sonelokimab's comparative performance while promoting the drug's superiority.
More negative than 90% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a class action lawsuit following a 90% stock price drop and allegations of misleading drug efficacy results.
More negative than 90% of ticker scores this week
The company is the subject of a class action lawsuit alleging investor harm.
More negative than 90% of ticker scores this week
The company is the subject of a class action lawsuit alleging investor harm.
More negative than 90% of ticker scores this week
The company is the subject of a class action lawsuit alleging investor harm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
−16.8%
Price agrees with the score
$12.54 vs $15.07 close before publication (Dec 8) · not market-adjusted
MLTX chart →
